HUE053949T2 - N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok - Google Patents

N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Info

Publication number
HUE053949T2
HUE053949T2 HUE10739701A HUE10739701A HUE053949T2 HU E053949 T2 HUE053949 T2 HU E053949T2 HU E10739701 A HUE10739701 A HU E10739701A HU E10739701 A HUE10739701 A HU E10739701A HU E053949 T2 HUE053949 T2 HU E053949T2
Authority
HU
Hungary
Prior art keywords
protofibrils
oligomers
terminally truncated
antibodies selective
truncated amyloid
Prior art date
Application number
HUE10739701A
Other languages
English (en)
Hungarian (hu)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of HUE053949T2 publication Critical patent/HUE053949T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE10739701A 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok HUE053949T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
HUE053949T2 true HUE053949T2 (hu) 2021-08-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10739701A HUE053949T2 (hu) 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP2448968B1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
RU2555526C2 (ru) 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
RS61717B1 (sr) 2014-07-10 2021-05-31 Bioarctic Ab Poboljšana antitela koja vezuju a-beta protofibril
JP2018522891A (ja) 2015-07-21 2018-08-16 バイオアークティック アーベー 凝集ペプチドを標的とする外傷性脳損傷の治療方法
WO2018011353A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
CN112805031A (zh) 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
DK4172199T3 (da) 2020-06-26 2025-08-18 Bioarctic Ab Alfa-synuklein-protofibril-bindende antistoffer
US20250163135A1 (en) 2021-07-09 2025-05-22 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2025506389A (ja) 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 p-タウ181レベルを使用した治療方法
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ES2235926T3 (es) * 1999-08-04 2005-07-16 The University Of Southern California Ensamblaje globular de proteina beta amiloide y sus usos.
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
PL1737891T3 (pl) * 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
KR101581733B1 (ko) * 2007-11-16 2015-12-31 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
LT2282758T (lt) * 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams

Also Published As

Publication number Publication date
US20120100129A1 (en) 2012-04-26
PL2448968T3 (pl) 2021-09-13
ES2864049T3 (es) 2021-10-13
EP2448968B1 (en) 2021-01-27
JP2017197531A (ja) 2017-11-02
DK2448968T3 (da) 2021-04-12
CA2765602A1 (en) 2011-01-06
JP6884025B2 (ja) 2021-06-09
AU2010267640A1 (en) 2012-01-19
LT2448968T (lt) 2021-05-10
SMT202100237T1 (it) 2021-05-07
CA2765602C (en) 2021-05-25
EP3892633A1 (en) 2021-10-13
PT2448968T (pt) 2021-04-30
CY1124034T1 (el) 2022-05-27
JP2019218362A (ja) 2019-12-26
WO2011001366A1 (en) 2011-01-06
JP2012532094A (ja) 2012-12-13
HRP20210611T1 (hr) 2021-05-28
AU2010267640B2 (en) 2015-03-05
US20230295283A1 (en) 2023-09-21
EP2448968A1 (en) 2012-05-09
SI2448968T1 (sl) 2021-07-30

Similar Documents

Publication Publication Date Title
HUE053949T2 (hu) N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok
PT2406284T (pt) Anticorpos anti-bcma
EP2406399A4 (en) MIRAC PROTEINS
DOS2010000009S (es) Botella
DK2480734T3 (da) Skinnesystem
DOS2010000006S (es) Botella
EP2448809A4 (en) CHANNEL SYSTEM
UY3958Q (es) Botella
BRPI1008979A2 (pt) meio de fixação
ITPD20090053U1 (it) Paradordi per banchine
ES1071736Y (es) Botella
DE112010001522A5 (de) Mobile förderbrücke
DE112010001392A5 (de) Vibrator
ITCT20090003U1 (it) Telepass -2 per non udenti
TH93312B (th) ขวด
FR2951765B1 (fr) Paumelle pour persiennes
FI20090460A0 (fi) Määritysmenetelmä
FI20090461A0 (fi) Määritysmenetelmä
FI20096331A0 (fi) Antibodin käyttö
DOS2009000147S (es) Botella
DOS2009000212S (es) Botella
CR10687S (es) Viga bloque
TH93146B (th) ขวด
UA19053S (uk) Пляшка
UA19147S (uk) Пляшка